Nathalie Levasseur
BCCA - Vancouver Cancer Centre
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Nathalie Levasseur as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05601440 · Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerCanadian Cancer Trials Group · recruiting · Breast Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:15 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed
- Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study.Eur J Cancer Care (Engl) · 201825 citationsRCR 1.6
- Aerobic exercise and CogniTIVe functioning in women with breAsT cancEr (ACTIVATE): A randomized controlled trial.Cancer · 202515 citationsRCR 3.9
- Breast Cancer Molecular Subtype as a Predictor of Radiation Therapy Fractionation Sensitivity.Int J Radiat Oncol Biol Phys · 202112 citationsRCR 0.5
- Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer.Clin Cancer Res · 20256 citationsRCR 1.3